For patients 45 years of age or older with clinical ASCVD, or 50 years of age or older with type 2 diabetes requiring medication and > 1 additional risk factor, and fasting triglycerides 135-499 mg/dL on maximally tolerated statin, with or without exetimibe, treatment with icosapent ethyl is recommended for ASCVD risk reduction.
We’re pleased to announce that posters presented at the 2019 National Lipid Association (NLA) Scientific Sessions are now available for viewing online!
The NLA accepted over 85 abstracts covering topics across the spectrum of clinical lipidology and cardiovascular disease prevention. This year’s abstracts topics included:
An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.
The presentation on Saturday, May 18, 4:40-4:50 p.m. included the total events analysis from the REDUCE-IT study, as first presented March 2019 and published in the Journal of the American College of Cardiology.